Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Txa6.0

Tranexamic Acid (topical) – Forschung

Überwiegend Mechanismus / Beobachtung

7 begutachtete Studien

Was die Evidenz sagt

Überwiegend Mechanismus / Beobachtung

Die meisten Studien zu Tranexamic Acid (topical) sind mechanistisch oder beobachtend statt RCTs, die einen klinischen Effekt messen — betrachte die Ergebnisse als vorläufig.

Die meiste Evidenz stammt aus mittelwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2014–2026 mit einer typischen Studiengröße von 44 Teilnehmenden.

Basierend auf 7 Studien · 2 Meta-Analysen · 3 RCTs · 114 Teilnehmende insgesamt

Konfidenz

Hohe Konfidenz

Nach Outcome

Skin tone & pigmentationReduktion von Melasma/hartnäckiger Pigmentierung, in kleinen Studien vergleichbar mit Hydrochinon (kosmetisches, kein gesundheitliches Ergebnis) · 8-12 Wochen
Überwiegend Mechanismus / Beobachtung6 Studien
Safety profile
Zu wenige bewertete Studien2 Studien
Heart & blood pressure
Zu wenige bewertete Studien1 Studie

Aktives Forschungsgebiet

5 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2024

201420202026

1Systematische Übersicht2025

Training, simulation, and guideline adoption are critical, particularly in resource-limited settings where advanced interventions for catastrophic bleeding are inaccessible.

Kostov S, Kornovski Y, Yordanov A, Slavchev S, Ivanova Y, Alkatout I, Watrowski R. · Journal of clinical medicine (2025)

In OB/GYN, APP allows for successful hemostasis in 75-90% of cases, with significantly lower mortality rates than trauma surgery.
Modern adjuncts-including early tranexamic acid, topical hemostatic agents, and multidisciplinary coordination-have transformed packing from a last-resort maneuver into an integrated component of staged hemorrhage control.
In conclusion, APP as a potentially life-saving maneuver within DCS requires integration into standardized, institution-wide hemorrhage protocols in OB/GYN.

Quelle ansehen

2Meta-Analyse2021

The ranking of relative efficacy compared with placebo in descending order was Q-switched Nd:Yag 1,064-nm laser, intense pulsed light, ablative fractional laser, triple combined cream, topical vitamin C, oral tranexamic acid, peeling, azelaic acid, microneedles, topical tranexamic acid.

Liu Y, Wu S, Wu H, Liang X, Guo D, Zhuo F. · Front Med (Lausanne) (2021)

Network meta-analysis of 59 RCTs ranking 14 melasma therapies
Oral TXA ranked above topical TXA, and lasers, triple-combination cream, and topical vitamin C all outranked topical TXA
Topical TXA carried a higher side-effect rate (36.75%) than oral TXA (17.6%) — the key counter-evidence that topical is not a top performer

Quelle ansehen

3RCTn=44 · small study2018

At 3 months, there was a 49% reduction in mMASI score in the TA group versus 18% in the control group.

Del Rosario E, Florez-Pollack S, Zapata L Jr, Hernandez K, Tovar-Garza A, Rodrigues M, Hynan LS, Pandya AG. · J Am Acad Dermatol (2018)

ORAL tranexamic acid (250 mg twice daily, 3 months) vs placebo, double-blind RCT (44 enrolled) — the best-quality TXA melasma RCT
Oral TXA gave a 49% mMASI reduction vs 18% for placebo, with no serious adverse events
Effect partly regressed after stopping; included as the higher-quality ORAL comparator, not topical

Quelle ansehen

4Meta-Analyse2024

Oral TXA showed the most substantial decrease in MASI scores, followed by injections and topical applications.

Calacattawi R, Alshahrani M, Aleid M, et al. · J Dermatolog Treat (2024)

Meta-analysis of 22 RCTs (1280 patients) of TXA delivered orally, topically, or by injection for melasma
TXA significantly reduced melasma severity, but ORAL TXA produced the largest MASI reduction, ahead of injection and topical routes
High heterogeneity; authors call for standardized administration protocols

Quelle ansehen

5RCTn=50 · small study2014

A significant decreasing trend was observed in the MASI score of both groups with no significant difference between them during the study (P < 0.05).

Ebrahimi B, Naeini FF. · J Res Med Sci (2014)

Double-blind 12-week split-face RCT in 50 women: 3% topical TXA on one side vs 3% hydroquinone + 0.01% dexamethasone on the other, twice daily
Both sides showed significant MASI reductions with no significant difference between topical TXA and the hydroquinone combination
Side effects were significantly more prominent with hydroquinone + dexamethasone than with TXA (P = 0.01)

6RCTn=20 · very small study2024

There were no statistically significant differences in PtGA scores between the 3% TA group and the 4% HQ group.

Yasnova N, Sirait SP, Rahmayunita G. · Acta Dermatovenerol Alp Pannonica Adriat (2024)

Double-blind 8-week split-face RCT in 20 skin-of-color subjects comparing 3% topical TXA cream vs 4% hydroquinone cream
Both produced significant mMASI declines at weeks 4 and 8 with no significant difference in patient global assessment
Concludes topical 3% TXA is as effective and safe as 4% HQ — but the trial is small (n=20)

7In vitro2026

TXA directly inhibited melanin synthesis in B16 melanoma cells, with an additive effect when combined with α-arbutin. In keratinocytes and macrophages, TXA attenuated inflammatory responses triggered by the plasminogen/plasmin (Plg/Plm) pathway.

Hushcha Y, Giuliani AL, Fernanda M, Bononi I, Mazziotta C, Rotondo JC, De Mattei M. · Cell Biol Int (2026)

In-vitro mechanism study: TXA directly inhibited melanin synthesis in B16 melanoma cells, additive with alpha-arbutin
TXA attenuated plasminogen/plasmin-pathway-driven inflammatory responses in keratinocytes and macrophages
Supports the proposed plasmin-inhibition mechanism, though evidence is cell-line, not human skin

Quelle ansehen

In der Forschungsbibliothek ansehen

Tranexamic Acid (topical) – Forschung

Überwiegend Mechanismus / Beobachtung

Damage Control Surgery in Obstetrics and Gynecology: Abdomino-Pelvic Packing in Multimodal Hemorrhage Management

Comparison of the Efficacy of Melasma Treatments: A Network Meta-Analysis of Randomized Controlled Trials.

Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma.

Tranexamic acid as a therapeutic option for melasma management: meta-analysis and systematic review of randomized controlled trials.

Topical tranexamic acid as a promising treatment for melasma.

The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial.

Insight Into the Cellular Activities of Tranexamic Acid as an Option for Melasma Treatment.